Treatment of geographic atrophy with subconjunctival sirolimus: Results of a phase I/II clinical trial

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 4, 2013, Pages 2941-2950

  Wong, Wai T ^a   Dresner, Samuel ^a   Forooghian, Farzin ^a   Glaser, Tanya ^a   Doss, Lauren ^a   Zhou, Mei ^a   Cunningham, Denise ^a   Shimel, Katherine ^a   Harrington, Molly ^b   Hammel, Keri ^b   Cukras, Catherine A ^a   Ferris, Frederick L ^a   Chew, Emily Y ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b EMMES CORPORATION   (United States)

Author keywords

Age related macular degeneration; Clinical trial; Geographic atrophy; Rapamycin; Sirolimus

Indexed keywords

RAPAMYCIN;

AGED; ALLERGY; ARTICLE; BACKACHE; CATARACT; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUSEN; ENDOCRINE DISEASE; EYE DISCHARGE; EYE IRRITATION; FEMALE; GEOGRAPHIC ATROPHY; HUMAN; LYMPHATIC SYSTEM DISEASE; MALE; MUSCULOSKELETAL DISEASE; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA HEMORRHAGE; RETINAL THICKNESS; SKIN DISEASE; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; UROGENITAL TRACT DISEASE; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; FEMALE; GEOGRAPHIC ATROPHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAOCULAR; MALE; OPHTHALMOSCOPY; PHOTOGRAPHY; PROSPECTIVE STUDIES; RETINA; RETINAL DRUSEN; SIROLIMUS; VISUAL ACUITY; VISUAL FIELD TESTS;

EID: 84876831911     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-11650     Document Type: Article

References (69)

1. Fleckenstein M, Charbel Issa P, Helb HM, et al. High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:4137-4144.
2. Sarks JP, Sarks SH, Killingsworth MC. Evolution of geographic atrophy of the retinal pigment epithelium. Eye. 1988;2:552-577.
3. Sunness JS, Gonzalez-Baron J, Applegate CA, et al. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. Ophthalmology. 1999;106:1768-1779.
4. Yehoshua Z, Rosenfeld PJ, Albini TA. Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures. Semin Ophthalmol. 2011;26:167-180.
5. Meleth AD, Wong WT, Chew EY. Treatment for atrophic macular degeneration. Curr Opin Ophthalmol. 2011;22:190-193.
6. Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron. 2012;75:26-39.
7. Pennesi ME, Neuringer M, Courtney RJ. Animal models of age related macular degeneration. Mol Aspects Med. 2012;33:487-509.
8. Mata NL, Lichter JB, Vogel R, Han Y, Bui TV, Singerman LJ. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina. 2013;33: 498-507.
9. Wong WT, Kam W, Cunningham D, et al. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. Invest Ophthalmol Vis Sci. 2010;51:6131-6139.
10. Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108:6241-6245.
11. Mata NL, Vogel R. Pharmacologic treatment of atrophic agerelated macular degeneration. Curr Opin Ophthalmol. 2010; 21:190-196.
12. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res. 2001;20:385-414.
13. Patel M, Chan CC. Immunopathological aspects of age-related macular degeneration. Semin Immunopathol. 2008;30:97-110.
14. Thakkinstian A, McEvoy M, Chakravarthy U, et al. The association between complement component 2/complement factor B polymorphisms and age-related macular degeneration: a HuGE review and meta-analysis. Am J Epidemiol. 2012;176: 361-372.
15. Thakkinstian A, McKay GJ, McEvoy M, et al. Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: a HuGE review and meta-analysis. Am J Epidemiol. 2011;173:1365-1379.
16. Thakkinstian A, Han P, McEvoy M, et al. Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet. 2006;15:2784-2790.
17. Gupta N, Brown KE, Milam AH. Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and agerelated macular degeneration. Exp Eye Res. 2003;76:463-471.
18. Vogt SD, Curcio CA, Wang L, et al. Retinal pigment epithelial expression of complement regulator CD46 is altered early in the course of geographic atrophy. Exp Eye Res. 2011;93:413-423.
19. Camardo J. The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation. Transplant Proc. 2003;35:18S-24S.
20. Vishnevetsky D, Patel P, Tijerino H, Gandhi PJ. Sirolimuseluting coronary stent. Am J Health Syst Pharm. 2004;61: 449-456.
21. Phillips BN, Wroblewski KJ. A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis. J Ophthalmic Inflamm Infect. 2010;1:29-34.
22. Shanmuganathan VA, Casely EM, Raj D, et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol. 2005;89:666-669.
23. Nussenblatt RB, Byrnes G, Sen HN, et al. A randomized pilot study of systemic immunosuppression in the treatment of agerelated macular degeneration with choroidal neovascularization. Retina. 2010;30:1579-1587.
24. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369:756-758.
25. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994;78:35-43.
26. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122:3589-3594.
27. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274-293.
28. Attur MG, Patel R, Thakker G, et al. Differential antiinflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. Inflamm Res. 2000;49:20-26.
29. Nuhrenberg TG, Voisard R, Fahlisch F, et al. Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J. 2005;19:246-248.
30. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335-340.
31. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35:7S-14S.
32. Dugel PU, Blumenkranz MS, Haller JA, et al. A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. Ophthalmology. 2012;119:124-131.
33. Krishnadev N, Forooghian F, Cukras C, et al. Subconjunctival sirolimus in the treatment of diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2011;249:1627-1633.
34. Mudumba S, Bezwada P, Takanaga H, et al. Tolerability and pharmacokinetics of intravitreal sirolimus. J Ocul Pharmacol Ther. 2012;28:507-514.
35. Fleckenstein M, Adrion C, Schmitz-Valckenberg S, et al. Concordance of disease progression in bilateral geographic atrophy due to AMD. Invest Ophthalmol Vis Sci. 2010;51:637-642.
36. Lindblad AS, Lloyd PC, Clemons TE, et al. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol. 2009;127:1168-1174.
37. Sunness JS, Applegate CA, Bressler NM, Hawkins BS. Designing clinical trials for age-related geographic atrophy of the macula: enrollment data from the geographic atrophy natural history study. Retina. 2007;27:204-210.
38. Spaide RF. Fundus autofluorescence and age-related macular degeneration. Ophthalmology. 2003;110:392-399.
39. Davis MD, Gangnon RE, Lee LY, et al. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol. 2005;123: 1484-1498.
40. Meleth AD, Mettu P, Agron E, et al. Changes in retinal sensitivity in geographic atrophy progression as measured by microperimetry. Invest Ophthalmol Vis Sci. 2011;52:1119-1126.
41. Feuer WJ, Yehoshua Z, Gregori G, et al. Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: a reanalysis of Age-Related Eye Disease Study Report No. 26. JAMA Ophthalmol. 2013;131:110-111.
42. Yehoshua Z, Rosenfeld PJ, Gregori G, et al. Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography. Ophthalmology. 2011;118:679-686.
43. Sen HN, Larson TA, Meleth AD, Smith WM, Nussenblatt RB. Subconjunctival sirolimus for the treatment of chronic active anterior uveitis: results of a pilot trial. Am J Ophthalmol. 2012; 153:1038-1042.
44. Schmitz-Valckenberg S, Jorzik J, Unnebrink K, Holz FG. Analysis of digital scanning laser ophthalmoscopy fundus autofluorescence images of geographic atrophy in advanced age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2002;240:73-78.
45. Sunness JS, Applegate CA, Gonzalez-Baron J. Improvement of visual acuity over time in patients with bilateral geographic atrophy from age-related macular degeneration. Retina. 2000; 20:162-169.
46. Curtis LH, Hammill BG, Qualls LG, et al. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 Medicare beneficiaries. Am J Ophthalmol. 2012;153: 1116-1124.
47. Belibi F, Ravichandran K, Zafar I, He Z, Edelstein CL. mTORC1/ 2 and rapamycin in female Han:SPRD rats with polycystic kidney disease. Am J Physiol Renal Physiol. 2011;300:F236-F244.
48. Gottschalk S, Cummins CL, Leibfritz D, Christians U, Benet LZ, Serkova NJ. Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism. Neurotoxicology. 2011;32:50-57.
49. Ferrante G, Presbitero P, Corrada E, et al. Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial. Am Heart J. 2012;163: 104-111.
50. Parikh PB, Gruberg L. Forget Mars and Venus, men and women are from the same planet after all. J Invasive Cardiol. 2012;24: 261-262.
51. Solinas E, Nikolsky E, Lansky AJ, et al. Gender-specific outcomes after sirolimus-eluting stent implantation. J Am Coll Cardiol. 2007;50:2111-2116.
52. Chang SB, Miron P, Miron A, Iglehart JD. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. J Surg Res. 2007;138:37-44.
53. Noh WC, Mondesire WH, Peng J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res. 2004;10:1013-1023.
54. Chong ZZ, Shang YC, Wang S, Maiese K. Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol. 2012;99:128-148.
55. Wilkinson JE, Burmeister L, Brooks SV, et al. Rapamycin slows aging in mice. Aging Cell. 2012;11:675-682.
56. Zhao C, Vollrath D. mTOR pathway activation in age-related retinal disease. Aging (Albany NY). 2011;3:346-347.
57. Zhao C, Yasumura D, Li X, et al. mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice. J Clin Invest. 2011;121:369-383.
58. Liu K, Shi N, Sun Y, Zhang T, Sun X. Therapeutic effects of rapamycin on MPTP-induced parkinsonism in mice. Neurochem Res. 2013;38:201-207.
59. Malagelada C, Jin ZH, Jackson-LewisV, Przedborski S, Greene LA. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci. 2010;30:1166-1175.
60. Edelstein J, Rockwell P. Okadaic acid induces Akt hyperphosphorylation and an oxidative stress-mediated cell death in serum starved SK-N-SH human neuroblastoma cells that are augmented by rapamycin. Neurosci Lett. 2012;531:74-79.
61. Chano T, Okabe H, Hulette CM. RB1CC1 insufficiency causes neuronal atrophy through mTOR signaling alteration and involved in the pathology of Alzheimer's diseases. Brain Res. 2007;1168:97-105.
62. Ma T, Hoeffer CA, Capetillo-Zarate E, et al. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS One. 2010;5: e12845.
63. Zhang Z, Wu X, Duan J, et al. Low dose rapamycin exacerbates autoimmune experimental uveitis. PLoS One. 2012;7:e36589.
64. Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012;335:1638-1643.
65. Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006;10:159-170.
66. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159-168.
67. Chen Y, Wang J, Cai J, Sternberg P. Altered mTOR signaling in senescent retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2010;51:5314-5319.
68. Foster DA, Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle. 2009;8:1026-1029.
69. Douglas LC, Yi NY, Davis JL, Salmon JH, Gilger BC. Ocular toxicity and distribution of subconjunctival and intravitreal rapamycin in horses. J Vet Pharmacol Ther. 2008;31:511-516.